Potential of Oral c-Abl Kinase Inhibitor Therapy

“Inhibikase Therapeutics Announces Publication Highlighting Mechanism of Disease and the Potential of Oral c-Abl Kinase Inhibitor Therapy for the Treatment of Parkinson’s Disease”

“Preclinical research and clinical safety and tolerability data supports continued development of IkT-148009 to potentially slow or halt progression of Parkinson’s disease”